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Abstract 
In well-resourced settings, reduced circulating maternal free placental growth factor (PlGF) aids 
in either predicting or confirming the diagnosis of preeclampsia, fetal growth restriction, 
stillbirth, preterm birth, and delivery within 14 days of testing when pre-eclampsia is suspected. 
This blinded, prospective cohort study of maternal plasma PlGF in women with suspected 
preeclampsia was conducted in antenatal clinics in Maputo, Mozambique. The primary 
outcome was the clinic-to-delivery interval. Other outcomes included: confirmed diagnosis of 
preeclampsia, transfer to higher care, mode of delivery, intrauterine fetal death, preterm birth, 
and low birth weight. Of 696 women, 95 (13·6%) and 601 (86·4%) women had either low (<100 
pg/ml) or normal (≥100 pg/ml) plasma PlGF, respectively. The clinic-to-delivery interval was 
shorter in low PlGF, compared with normal PlGF, women (median 24 days [IQR 10 - 49] vs 44 
[24 - 81], p=0.0042). Also, low PlGF was associated with a confirmed diagnosis of preeclampsia, 
higher blood pressure, transfer for higher care, earlier gestational age delivery, delivery within 
7 and 14 days, preterm birth, Cesarean delivery, lower birth weight, and perinatal loss. In urban 
Mozambican women with symptoms and/or signs suggestive of preeclampsia, low maternal 
plasma PlGF concentrations are associated with increased risks of adverse pregnancy 
outcomes, whether or not the diagnosis of pre-eclampsia is confirmed. Therefore, PlGF should 
improve the provision of precision medicine to individual women and improve pregnancy 
outcomes for those with preeclampsia or related placenta-mediated complications. 
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Background 
Complicating an estimated 3-10% of pregnancies, the hypertensive disorders of pregnancy 
(HDPs) account for an estimated 46,000 maternal and 500,000 perinatal deaths annually, with 
>99% of these deaths occurring in less-developed countries, including Mozambique (1;2). The 
most dangerous of the HDPs is preeclampsia, the origins of which lie in a mixture of maternal 
and placental factors (3;4). Currently, delivery is the only mechanism by which to initiate the 
resolution of preeclampsia (3), whether that delivery is spontaneous or iatrogenic. Iatrogenic 
delivery is predicated on a timely diagnosis of preeclampsia, with additional safeguards being 
offered through avoidance of, and response to, severe maternal hypertension and eclampsia 
for women and risks of prematurity for fetuses prior to term (1).  
The diagnosis of the HDPs, especially preeclampsia, largely remains reliant on women having 
access to accurate blood pressure (BP) measurement, estimation of urinary protein and testing 
for end organ complications. Women in their community and admitted to hospital with a HDP 
can be assessed for actuarial risk using either the demographics-, symptom- and sign-based 
miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) tool, especially when supplemented by 
pulse oximetry (5;6). or the demographics-, symptom-, sign- and laboratory test-based fullPIERS 
tool (7). 
In well-resourced settings, low concentrations of circulating maternal free placental growth 
factor (PlGF) (sometimes relative to soluble fms-like tyrosine kinase-1 [sFlt-1]), or 
antiangiogenic factor predominance, aids in either predicting or confirming the diagnosis of 
preeclampsia, fetal growth restriction of placental origin (FGR), stillbirth and preterm birth in 
general and high-risk maternal populations (8-13), and, perhaps, spontaneous term labor (14). 
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In particular, Chappell et al reported high sensitivity of (low) PlGF in predicting delivery within 
14 days of testing when preeclampsia is suspected (10). Thus, PlGF and sFlt-1 reflect placental 
health and angiogenic factor balance and are of particular diagnostic assistance when 
measured prior to term (4;8;10;12). However, whether or not low maternal PlGF may 
strengthen the often-limited diagnostic capabilities of health practitioners caring for women in 
less-developed settings has not been determined. In Mozambique, such limitations include 
poor access to diagnostic testing as mentioned above, as well as limited knowledge of 
preeclampsia and delays in seeking care (15-18).  
In response to the gaps in care discussed above, we determined the ability of maternal plasma 
free PlGF to identify those women at risk of complicated preeclampsia when preeclampsia was 
suspected in the course of antenatal care in Maputo city, Mozambique. 
Methods 
We undertook this blinded, prospective cohort study of consenting women with suspected 
preeclampsia in two large antenatal clinics in Maputo, Mozambique from August 2014 to 
February 2015. Monthly, each clinic provided approximately 350 mixed first and follow-up 
antenatal visits. To be eligible, women were ≥16 years old, estimated to be ≥20+0 weeks 
pregnant, and identified to have either symptoms suggestive of preeclampsia (headache, visual 
disturbance, or epigastric pain) and/or hypertension (either a systolic BP [sBP] ≥140 mmHg 
and/or diastolic BP [dBP] ≥90 mmHg). Blood pressure was measured with women sitting and 
with the right arm supported at the level of the heart as part of routine antenatal care, using 
Omron Hem-4500-Sole (BPM solar)® fully-automated blood pressure monitors. Blood pressure 
measurement was repeated if hypertension was detected on the first reading and the lower 
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reading recorded in the data collection form. Normotensive readings were not repeated. The 
presence of significant proteinuria (≥2+ by dipstick) was not an eligibility criterion.  
Eligible women were identified and approached by the nurses providing antenatal care, and 
subsequently consented by a study field assistant trained to collect written informed consent 
for participation. Enrolled women were reimbursed for transportation to attend antenatal care 
and were followed until delivery. Facility management, including delivery decisions, were made 
by clinicians not involved in the study and in compliance with Ministry of Health guidelines. The 
study protocol was approved by the national bioethics committee in Mozambique. 
At the time of the antenatal visit that triggered eligibility, venous blood was collected, plasma 
prepared, and PlGF assayed using the Alere Triage® monoclonal antibody-based immunoassay 
and meter (Alere, San Diego, CA), according to the manufacturer’s instructions. Maternal 
plasma PlGF concentrations were quantified within the measurable range of the assay (12 – 
3000 pg/ml) and classified as either normal (≥100 pg/ml), low (13 – 99 pg/ml), or very low (≤12 
pg/ml), as undertaken in PELICAN (19). Women who were between 20+0 – 27+6 weeks’ 
gestation, who did not fulfil the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) diagnostic criteria for preeclampsia (20), but whose PlGF concentration was 
<100 pg/ml were reassessed by PlGF 7 – 14 days later, and the latter result used for the data 
analyses. The research laboratory staff was blinded to the clinical course of participating 
women and the clinicians and clinical data collectors were blinded to the PlGF results. 
The primary outcome for analysis was median time-to-delivery following the informative PlGF 
assay (‘clinic’). Other outcomes of interest included: confirmed diagnosis of preeclampsia, 
transfer to higher care, mode of delivery, intrauterine fetal death, preterm birth (<37+0 weeks), 
 Page 8 
 
and low birth weight (<10th centile for GA derived from the Intergrowth-21st chart (21)). For 
outcome adjudication, pre-eclampsia was defined as hypertension and either significant 
proteinuria or other maternal organ dysfunction, according to the 2014 ISSHP criteria (20). 
Adjudication of a diagnosis of preeclampsia was performed by obstetricians not involved in the 
women’s care and blinded to the PlGF results. 
The sample size was based on the PELICAN study (625 women) (19), and temporal estimate 
made for sufficient recruitment.  
Statistical analyses: Kaplan-Meier curves were derived and Mantel-Cox log-rank test survival 
analyses performed to describe the primary outcome. Fisher’s exact and chi-square tests were 
used for categorical variables and Mann-Whitney U and Kruskal-Wallis with Dunn’s multiple 
comparisons tests were used for continuous variables. Using Prism 5·0 (GraphPad, San Diego, 
CA), statistical significance was set at p<0.05 for the primary comparison and Dunn’s tests, and 
<0.01 for other comparisons (to adjust for multiple comparisons). 
Results 
During the study period 723 women (≈5.9% of antenatal visits) were approached for 
recruitment, of whom 710 (98·2%) consented to participation (Figure 1). Upon review, 2 (0·3%) 
consented women did not meet eligibility criteria and were excluded from the analyses. Of 708 
eligible and consented women, 12 (1·7%) were lost to follow-up, resulting in an informative 
cohort of 696 women. No participating women died. 
Using the prespecified criteria, 601 (86·4%), 85 (12·2%), and 10 (1·4%) women had normal, low 
and very low plasma PlGF concentrations, respectively. Therefore, to strengthen statistical 
power, women were classified according to PlGF results into either low plasma PlGF (<100 
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pg/ml) or normal plasma PlGF (≥100 pg/ml) (Table 1). Women with low PlGF (compared with 
those with normal PlGF) were of similar age, parity, gestational age at PlGF testing, HIV status, 
significant proteinuria status, and symptom burden, and had similar hemoglobin concentrations 
and antihypertensive therapy use (Table 1).  
The distribution of individual PlGF measurements is shown in Figure 2. 
The clinic-to-delivery interval was shorter in low PlGF, compared with normal PlGF, women 
(median 28 days [IQR 15 - 58] vs 48 [26 - 87], p<0.0001; Table 1, Figure 3). In both groups, this 
was consistent between women who were adjudicated to have and have not developed 
preeclampsia (Figure 2). In addition, women with low PlGF were more likely to have a 
confirmed diagnosis of preeclampsia, have higher blood pressure, have higher serum creatinine 
concentrations, be transferred for higher care (particularly to a referral center), deliver two 
weeks earlier (although usually at term), deliver within 7 and 14 days, deliver by Cesarean 
section, and suffer perinatal losses, than women with normal PlGF. Birth weights tended to be 
lower in women with low PlGF, but the observed 200g difference did not reach the prespecified 
level for statistical significance (p=0·0129). For women with hypertension (compared with those 
without, irrespective of PlGF concentration), the clinic-to-delivery intervals were 44 days [21 - 
77] and 39 days [22 - 78.5], respectively (p=0.8670). 
For delivery within 14 days, the primary outcome of the PELICAN study(10), low PlGF had a 
sensitivity of 0·28 [95% confidence interval (CI) 0·20 - 0·39], specificity of 0·89 [95% CI 0·87 – 
0·92], positive predictive value (PPV) of 0·30 [95% CI 0·21 – 0·40], and negative predictive value 
(NPV) of 0·89 [95% CI 0·86 – 0·91]. For women with hypertension (compared with those 
without, irrespective of PlGF concentration), hypertension identified 56 of 395 (14·2%) women 
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who delivered within 14 days, compared with non-hypertension (37/265 (14·0%)) (sensitivity 
0·14 [95% CI 0·10 - 0·17], specificity 0·88 [95% CI 0·84 - 0·91], PPV 0·59 [95% CI 0·49 - 0·70], and 
NPV 0·44 [95% CI 0·40 - 0·48]). 
When comparing groups between women with either normal or low PlGF and either confirmed 
preeclampsia or not, differences between the PlGF groups were confirmed (p<0·01), but no 
differences were observed within either normal or low PlGF whether or not women had a 
confirmed diagnosis of preeclampsia (p≥0·01), by Kruskal Wallis and Dunn’s analyses.  
Of those 107 women from both low and normal PlGF groups who were screened at term (≥37+0 
weeks), increasing maternal plasma PlGF was linearly associated with a longer clinic-to-delivery 
interval (slope: 0·004 ± 0·001; r2: 0·13; p=0·0002),. 
Discussion 
In this study we have determined that among women with suspected preeclampsia who 
attended large antenatal clinics in Maputo, Mozambique, low maternal plasma PlGF identified 
women destined to deliver soon and have more complicated pregnancies, irrespective of 
whether or not they had a confirmed diagnosis of preeclampsia. In this respect, PlGF did not 
perform worse than, and probably outperformed, any diagnosis of hypertension. 
The major strength of this study is that it is the first assessment of the prognostic capacity of 
PlGF in antenatal clinics in a less-developed country. These clinics are located in facilities in 
Maputo, and, therefore, the cohort should be representative of urban pregnant women in 
Mozambique. In addition, clinical outcome assessment and PlGF measurements were 
performed by individuals blinded to PlGF results and clinical courses, respectively. In addition, 
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we compared birth weights using the Intergrowth 21st standards (21), rather than an arbitrary 
birth weight cut-off such as 2500 g. 
The major limitations of the study are the limited power of the study that required grouping 
together of the women with maternal plasma PlGF both ≤12 pg/ml and 13 – 99 pg/ml, and the 
inaccuracies of pregnancy dating inherent in a health system in which women generally book 
for care at 18 – 22 weeks’ gestation. Consequently, some women were deemed to have had 
pregnancies of 45 weeks’ duration; a rare event with accurate pregnancy dating. This 
uncertainty about gestational age estimation strengthened the rationale for our choice to use 
the stable cut-off of 100 pg/ml to discriminate between normal and low PlGF, rather than the 
alternative approach of using the varying 5th centile for gestational age.  
In addition, due to limitations of access to ongoing clinical surveillance and laboratory testing, it 
is probable that some women, with both normal and low PlGF, for whom a diagnosis of 
preeclampsia could not be confirmed did, indeed, have the clinical syndrome of preeclampsia. 
Given our high recruitment and follow-up rates, we do not believe that the ethics committee-
approved transport vouchers contributed to any socioeconomic bias in this cohort of urban 
poor women. 
Our findings in this study confirm those made in more-developed countries relating low 
maternal plasma concentrations of PlGF with imminent delivery and increased identification of 
preeclampsia, FGR, perinatal death risk and early birth (9-13). In particular, these data replicate 
the findings of the PELICAN project, in which 40.7% of 270 women with preeclampsia recruited 
prior to 37+0 weeks’ gestation delivered within 14 days (sensitivity 0·96 [0·89 – 0·99], specificity 
0·56 [0·49 – 0·63], PPV 0·44 [0·36 – 0·52], NPV 0·98 [0·93–0·995]) (10); in this study, 28·4% of 
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women with low PlGF delivered within that timeframe, with lower sensitivity (0·28), higher 
specificity (0·89) and similar PPV (0·30) and NPV (0·89).  
In this study, while we observed differences in the rates of confirmed diagnoses of 
preeclampsia, we did not observe any differences in either birth weight or birth weight <10th 
centile between women with normal and low maternal plasma PlGF concentrations, although 
there was a trend towards a lower birth weight that did not meet our prespecified threshold of 
p<0·01. This was unanticipated, due to our previous experience of the strong performance of 
low PlGF to discriminate between FGR fetuses and constitutionally-small fetuses (12). It may be 
that the acknowledged inaccuracies in determining expected dates of delivery in this study and, 
therefore, gestational age at delivery, obscured the anticipated association between low PlGF 
and FGR.  
We deem the non-specific identification of presumptively placenta-mediated risk, rather than 
solely preeclampsia-related risk, to be important. For practitioners in all settings, but 
particularly those providing care to women in less-developed settings, what matters is the 
ability to identify risk for individual women so that antenatal surveillance and timing-of-delivery 
decisions can be tailored. In this context, risk classification according to biomarker-based 
precision medicine to group individual women according to their personal risks of adverse 
outcomes offers an important step towards achieving equity in maternity care. In addition, 
identifying whether or not an individual woman’s time-to-delivery may be foreshortened is 
more important in less-resourced settings due to inadequacy of neonatal services outside 
referral centers that are often hours’ travel time away from where women primarily encounter 
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the health system. In this study, we have determined that PlGF offers such risk classification 
capacity, irrespective of whether or not the woman has clinically-confirmed preeclampsia.  
In addition, these data are suggestive of a role for the well-recognized fall in PlGF towards term 
in the prediction of the onset of term labor (22), especially in the context of low labor induction 
and Cesarean delivery rates. It may be that the reduction in proangiogenic factors such as PlGF 
at term aid placental separation and are protective against postpartum hemorrhage. 
For women with pregnancy hypertension, it is unclear what interaction exists between time-of-
disease risk estimation using PlGF and the miniPIERS and fullPIERS tools (5-7). Therefore, we 
believe that integrating PlGF with both miniPIERS and fullPIERS, and other candidate 
biomarkers such as glycosylated fibrionectin (23), is an important research priority. Also, to be 
globally-relevant and to reduce health access inequities, the accurate measurement of PlGF 
needs to be made available to all cadres of health workers as a whole blood point-of-care test. 
Currently, the Triage® device costs $2,267 USD, each PlGF test, $27 USD, and each daily 
standard (high and low), $5 USD. To become globally-relevant, a whole blood point-of-care test 
would need to provide an accurate result for <$200 per maternal or perinatal life saved. 
Either following, or in parallel with, these steps, monitored urban and rural, population-based 
implementation of PlGF through a stepped wedge cluster randomized controlled trial design 
would facilitate health system assessment of the role of this biomarker in the care of women in 
less-developed countries. In such a trial, we would envisage using PlGF to guide transfer to 
facilities where women can receive increased clinical, laboratory, and ultrasound surveillance as 
well as guiding the counseling of women and their families regarding possible imminence of 
birth in women with low PlGF.  
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Perspectives 
There has been an increasing body of evidence to support the ability of plasma PlGF to identify 
women whose pregnancies are complicated by placental complications (e.g., preeclampsia and 
fetal growth restriction of placental origin) in high income country facilities, not solely 
preeclampsia. However, we are not aware of a previous assessment of the diagnostic 
performance of PlGF in women with suspected preeclampsia in a low- or middle-income 
country. We have confirmed the diagnostic performance of maternal plasma PlGF in identifying 
women at increased of imminent delivery in clinics in Maputo, Mozambique. In addition, we 
have confirmed the performance of PlGF in identifying pregnancy complications beyond 
preeclampsia. Therefore, PlGF should improve the provision of precision medicine to individual 
women and improve pregnancy outcomes for those with preeclampsia or related placenta-
mediated complications in all settings. This would assist in triaging women with suspected 
complications so that those most at risk are prioritized within stretched health systems. A 
whole blood point-of-care PlGF assay would make this test available to women wherever they 
encounter the health system. 
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Novelty and Significance 
What Is New? 
• First real-world assessment of PlGF diagnostic performance in urban LMIC antenatal clinics 
• Low PlGF identifies a group of women at risk of imminent birth whether or not 
preeclampsia is confirmed 
What Is Relevant? 
• All women included in the study were hypertensive at recruitment 
• All women included in the study had symptoms suggestive of preeclampsia 
• Significant dipstick proteinuria was not an eligibility criterion 
Summary 
PlGF identifies pregnancies complicated by placental complications and could be used in all 
settings to assist in triaging women with suspected complications so that those most at risk are 
prioritised within stretched health systems. A whole blood point-of-care PlGF assay would make 
this test available to women wherever they encounter the health system. 
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Figure 1. Flow chart of women in the study 
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Figure 2. Distribution of placental growth factor by gestational age at assessment.  
The population was divided into women with normal PlGF (≥100 pg/ml (n=601, squares)) and 
low PlGF (<100 pg/ml (n=95, circles))s, each with/without a confirmed diagnosis of 
preeclampsia. The limits of detection of the assay were 12 and 3000 pg/ml (lower and upper 
dotted lines, respectively). 
PET, preeclampsia; PlGF, placental growth factor 
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Figure 3. Kaplan-Meier survival curve of clinic-to-delivery interval between women with normal 
and low maternal plasma placental growth factor. 
Women with low PlGF had shorter clinic-to-delivery intervals (median 24 days), irrespective of 
whether they had (26 days) or did not have (23 days) preeclampsia, compared with women 
with normal PlGF (median 44 days), irrespective of whether they had (50 days) or did not have 
(42 days) confirmed preeclampsia. 
PET, preeclampsia; PlGF, placental growth factor 
